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Rett syndrome (RTT) is a pervasive neurodevelopmental disorder mainly linked to mutations in the gene encoding the methyl-
CpG-binding protein 2 (MeCP2). Respiratory dysfunction, historically credited to brainstem immaturity, represents a major
challenge in RTT. Our aim was to characterize the relationships between pulmonary gas exchange abnormality (GEA), upper
airway obstruction, and redox status in patients with typical RTT (n = 228) and to examine lung histology in aMecp2-null mouse
model of the disease. GEA was detectable in ∼80% (184/228) of patients versus ∼18% of healthy controls, with “high” (39.8%) and
“low” (34.8%) patterns dominating over “mixed” (19.6%) and “simple mismatch” (5.9%) types. Increased plasma levels of non-
protein-bound iron (NPBI), F
2
-isoprostanes (F
2
-IsoPs), intraerythrocyte NPBI (IE-NPBI), and reduced and oxidized glutathione
(i.e., GSH and GSSG) were evidenced in RTT with consequently decreased GSH/GSSG ratios. Apnea frequency/severity was
positively correlated with IE-NPBI, F
2
-IsoPs, and GSSG and negatively with GSH/GSSG ratio. A diffuse inflammatory infiltrate
of the terminal bronchioles and alveoli was evidenced in half of the examinedMecp2-mutant mice, well fitting with the radiological
findings previously observed in RTT patients. Our findings indicate that GEA is a key feature of RTT and that terminal bronchioles
are a likely major target of the disease.
1. Introduction
Rett syndrome (RTT), for a long time included among
the Autism Spectrum Disorders (ASDs), is a nosologically
distinct, genetically determined neurological entity associ-
ated in up to 95% of cases to de novo loss-of-function
mutations in the X-chromosome-linked gene encoding the
methyl-CpG-binding protein 2 (MeCP2) [1]. MeCP2, a ubiq-
uitous protein particularly abundant in brain, is known to
either activate or repress transcription [2, 3], is critical to
the function of several types of cells (i.e., neurons and
astroglial cells), and targets several genes essential for neu-
ronal survival, dendritic growth, synaptogenesis, and activity
dependent plasticity [4].
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In its classical clinical presentation, RTT affects heterozy-
gous females and shows a typical 4-stage neurological regres-
sion after 6 to 18 months of apparently normal development.
RTT is a relatively rare disease, affecting about 1 : 10,000
female live births, although it represents the second most
common cause of severe intellectual disability in the female
gender [5, 6]. Preserved speech, early seizure, and congenital
are well-known atypical variants often linked to mutations
in genes other than MECP2, that is, the cyclin-dependent
kinase-like 5 (CDKL5) in the early seizure variant and the
forkhead boxG1 (FOXG1) in the congenital variant [6, 7].
Breathing disorders are considered a hallmark feature
of RTT and represent a major clinical challenge [8]. To
date, a large number of studies have been focusing on this
particular characteristic of the disease, both in the clinical and
experimental environments. Breathing abnormalities in RTT
variably include/feature breath holdings, apneas, apneusis,
hyperventilation, rapid shallow breathing, and spontaneous
Valsalva maneuvers [9]. In particular, a highly irregular
respiratory rhythm particularly during daytime is consid-
ered among the key symptoms of RTT [9–11]. Cumulating
evidence indicates a predominantly hyperventilatory pattern
with increased respiratory frequency and decreased expira-
tory duration, which is associated with frequent episodes
of breath-holding/obstructive apnea or Valsalva breathing
against closed airways during wakefulness [12–14]. However,
the breath-holding/obstructive apnea phenotype of RTT is
often confused in the related clinical literature with central
apnea, which has fundamentally distinct neurological mech-
anisms [9, 15–26].Thewide spectrumof respiratory disorders
detectable in RTT patients has been historically credited to
brainstem immaturity and/or cardiorespiratory autonomic
dysautonomia [9, 27, 28]. However, as the pathogenesis
of the respiratory dysfunction in RTT appears far from
being completely understood, alternative or complementary
hypotheses can be formulated [29].
In particular, the potential role of oxidative stress (OS)
mediators and the role of the lung itself in the pathogen-
esis of the respiratory dysfunction in the human disease
are incompletely understood. More recently, biochemical
evidence of redox imbalance and, in particular, enhanced
lipid peroxidation, in blood samples from RTT patients, was
further confirmed in primary skin fibroblasts cultures from
patients [30–37], although the nature of the relationship, that
is, whether causal or correlational, between MECP2 gene
mutation and abnormal redox homeostasis remains currently
unclear. Significantly increased pulmonary alveolar-arterial
gradient forO
2
, highly suggestive for an abnormal pulmonary
gas exchange, has been previously described by our group
in the majority of the examined RTT patients [29] and was
found to be related in about a half of the cases to a pul-
monary radiological picture partially mimicking that of the
respiratory bronchiolitis-associated interstitial lung disease
(RB-ILD) [38], one of the three lung conditions showing
the stronger epidemiological association with tobacco smoke
[39, 40].
However, to date, no information exists regarding the
lung pathological lesions underlying the radiological changes
observed in RTT patients.
Aims of the present study were to characterize the possi-
ble role of pulmonary gas exchange abnormality (GEA) in the
pathogenesis of redox imbalance and respiratory dysfunction
in RTT and to evaluate lung histology in an experimental
mouse model of MeCP2 deficiency.
2. Methods
2.1. Subjects. In the present study, a total of 𝑛 = 228
female patients with a clinical diagnosis of typical RTT and
demonstrated MECP2 gene mutation were recruited (mean
age, 12.9 ± 7.9 years; range, 1.5–32 years). RTT diagnosis
and inclusion/exclusion criteria were based on a revised
nomenclature consensus [6]. Clinical severity was assessed
by the use of the clinical severity score (CSS), a specifically
validated clinical rating system based on 13 individual ordi-
nal categories measuring clinical features common in the
disease [7]. Respiratory dysfunction on a clinical basis was
categorized based on the corresponding Percy scale item (+
asminimal hyperventilation and/or apnea; ++ as intermittent
hyperventilation and/or apnea; and +++ as hyperventilation
and/or apnea with cyanosis) [41].
The corresponding 𝑧-scores for body weight, height, head
circumference, and body mass index were calculated on the
basis of validated RTT-specific growth charts [42]. Clinical
stages distribution was: stage I (𝑛 = 4), stage II (𝑛 = 69), stage
III (𝑛 = 92), and stage IV (𝑛 = 63). All the patients were
admitted to the Rett Syndrome National Reference Centre of
the University Hospital of the Azienda Ospedaliera Universi-
taria Senese. A total of 114 healthy and typically developed
female subjects of comparable age (mean age, 12.9 ± 7.8
years; range, 1.6–32 years) were also enrolled in the study
as a control population. Blood samplings from the control
group were performed during routine health checks, sports,
or blood donations obtained during the periodic checks.
All the examined subjects were on a typical Mediterranean
diet. The study was conducted with the approval by the
Institutional Review Board and all informed consents were
obtained from either the parents or the legal tutors of the
enrolled patients.
2.2. Oxidative Stress (OS) Markers and Antioxidant
Defence Evaluations
2.2.1. Blood Sampling. Blood was collected in heparinized
tubes and all manipulations were carried out within 2 h after
sample collection. An aliquot (90𝜇L) of each samplewas used
for reduced and oxidized glutathione assay. Blood samples
were centrifuged at 2400×g for 15min at 4∘C; the platelet
poor plasma was saved and the buffy coat was removed
by aspiration. RBCs were washed twice with physiologic
solution (150mM NaCl). An aliquot of packed erythrocytes
was resuspended in Ringer solution (125mM NaCl, 5mM
KCl, 1mM MgSO
4
, 32mM N-2 hydroxyethylpiperazine-N-
2-ethanesulfonic acid (HEPES), 5mM glucose, and 1mM
CaCl
2
), pH 7.4 as a 50% (vol/vol) suspension for the deter-
mination of intraerythrocyte NPBI. Plasma was used for the
NPBI assay.
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2.2.2. Intraerythrocyte and Plasma Non-Protein-Bound Iron
(IE-NPBI). Generally, NPBI is considered not only an OS
marker but a prooxidant factor. In particular, IE-NPBI is a
critical marker of hypoxia. IE-NPBI (nmol/mL erythrocyte
suspension) was determined as a desferrioxamine- (DFO)
iron complex (ferrioxamine) as previously reported [29]
Plasma NPBI (nmol/ml) was determined as above reported
for IE-NPBI [29].
2.2.3. Plasma F
2
-Isoprostanes (F
2
-IsoPs). F
2
-IsoPs, gener-
ated by free radical-catalyzed peroxidation of phospholipid-
bound arachidonic acid, are considered specific and reliable
OS markers in vivo. F
2
-IsoPs were determined by a gas
chromatography/negative ion chemical ionization tandem
mass spectrometry (GC/NICI-MS/MS) analysis after solid
phase extraction and derivatization steps [43]. For F
2
-IsoPs
the measured ions were the product ions at m/z 299 and
m/z 303 derived from the [M−181]− precursor ions (m/z 569
and m/z 573) produced from 15-F
2t-IsoPs and PGF2𝛼-d4,
respectively [43].
2.2.4. Blood Reduced and Oxidized Glutathione. Glutathione
(𝛾-L-glutamyl-L-cysteinyl-glycine) is a tripeptide that plays
an important role in protecting cells and tissues against OS
[44]. Under nonoxidative and nitrosative stress conditions,
over 98% of the glutathione is considered to be in the reduced
form (GSH) [45], whereas under oxidative conditions GSH is
converted to glutathione disulfide (GSSG), its oxidized form,
with a resulting decrease in the GSH/GSSG ratio. As blood
glutathione concentrations may reflect glutathione status in
other less accessible tissues, measurement of both GSH and
GSSG in blood has been considered essential as an index
of whole-body glutathione status and a useful indicator of
antioxidant defence [46]. Specifically, the GSH/GSSG ratio
reflects the cellular redox status. Blood GSH and GSSG
levels were determined by an enzymatic recycling procedure
according to Tietze [47] and Baker et al. [48].
2.3. Cardiorespiratory Monitoring. In order to analyze the
occurrence of apnoeas and hypopneas, breathing monitoring
was carried out in RTT patients during wakefulness and sleep
state by using portable polygraphic screening devices (SOM-
NOwatchTMplus, SOMNOmedics, Randersacker, Germany;
importer for Italy Linde Medicale srl) for a mean recording
time of 13 ± 0.5 h for each state. Monitoring included nasal
airflow, arterial oxygen saturation by pulse oximetry, and
respiratory efforts by abdominal and thoracic bands. Breath-
ing patterns were analyzed for the presence of apnoeas and
hypopnoeas according to the standardized definitions by the
AmericanAcademy of SleepMedicine [49] and theAmerican
Academy of Pediatrics [50]. Apnoeas were defined as a >90%
airflow decrease for 10 sec, while hypopnoeas were defined
as a >50% airflow reduction for ∼10 sec associated with a
decrease of 3% in oxygen saturation [49]. Apnoeas were
categorized as obstructive (i.e., cessation of airflow for 10 sec
with persistent respiratory effort), central (i.e., cessation of
airflow for 10 sec with no respiratory effort), and mixed (an
apnea that begins as a central apnea and ends up as an
obstructive apnea). Apnoeas were further categorized asmild
(10 to 15 sec), moderate (15 to 30 sec), and severe (>30 sec)
on the basis of their recorded duration. The apnea-hypopnea
index (AHI) was defined as the number of obstructive and
central apnoeas and hypopnoeas per hour of sleep and
calculated by dividing the total number of events by the total
sleep time. An AHI > 15 during sleep was considered to
be indicative of obstructive sleep apnea/hypopnea syndrome
(OSAHS). All records were reviewed by a pneumologist with
a longstanding expertise in OSAHS (i.e., coauthor M.R.).
2.4. Pulmonary Gas Exchange Analysis. Pulmonary gas
exchange was evaluated from direct measurements of total
volume (𝑉tot), respiratory rate, and expiratory fractions of
CO
2
and O
2
by using a portable, commercially available gas
analyzer (Hanky Hapy, version 1.2; Ambra Sistemi; Pianezza,
Turin, Italy), as previously described [29]. The method to
evaluate pulmonary gas exchange works essentially as a
multicompartment model (Figure 1) and is essentially based
on the classical West function [51]. Air gas sampling was
obtained by applying a facial mask of appropriate size con-
nected to the gas analyzer. Low invasivity and the easy-to-
use features of the method allowed us to evaluate a relatively
large population size of patients. Actually, the methodol-
ogy does not require patient’s cooperation and is therefore
easily applicable to RTT patients and has been proven to
be sufficiently simple, noninvasive, accurate, and precise in
determining alveolar-arterial gradient lung exchange for O
2
and ventilation/perfusion ratio (𝑉/𝑄) inequalities. Respira-
tory rate, total ventilation, and expired gas composition were
measured during either a 60-sec or 120-sec time period.
𝑉/𝑄distribution parameterswere calculated by aminimizing
mathematical function in order to reset to zero the differences
between measured and calculated PaO
2
and PaCO
2
. All
respiratory measurements were carried out in duplicate, and
the averages used for data analysis. Arterial blood for gas
analyses was sampled from either the humeral or the radial
artery, and PaO
2
, PaCO
2
, and pH values were determined
using a commercially available blood gas analyzer (ABL520
Radiometer; Radiometer Medical A/S; Copenhagen, Den-
mark). Ventilation-perfusion (𝑉/𝑄) inequalities (i.e., GEA)
were classified as low, high, mixed, and simple mismatch. A
“low” pattern indicates the presence of perfusion in poorly
ventilated pulmonary areas; a “high” pattern points out the
existence of high ventilation in poorly perfused pulmonary
areas; a mixed pattern indicates a combination of the former
two patterns; a simple “mismatch” was defined as a 𝑉/𝑄
uncoupling showing amodest fraction of low𝑉/𝑄 ratios (1 to
0.1) and amodest fraction of high𝑉/𝑄 ratios (1 to 10). In order
to account for the low PaCO
2
values often encountered in
RTT patients, standard PaO
2
was calculated with the formula
PaO
2
= 1.66 × PaCO
2
+ PaO
2
− 66.4, according to Sorbini et
al. [52].
2.5. RTT Mouse Model: Murine Lung Histology. A total
of (𝑛 = 4) Mecp2 null mice and (𝑛 = 4) wild-type
matched mice were examined. Experimental subjects were
derived fromheterozygous B6.129SF1-Mecp2tm1Jae knockout
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Figure 1: Algorithm for the noninvasive assessment of pulmonary gas exchange (Hanky Hapy gas analyzer version 1.2).
females (Mecp2+/−) [53]. Females were originally crossed to
C57BL6/J for one generation, followed by breeding amongst
offspring of the same generation with breeder changes, and
weremaintained on amixed background.Mixed background
reduced mortality and was necessary to obtain the high
numbers ofmice required by extensive analysis. Age-matched
littermates were used in all experiments to control for
possible effects of genetic background unrelated to theMecp2
mutation [54]. Mice were killed by decapitation at the thirty-
eighth day of life; their lungs were removed rapidly and
immediately frozen on liquid nitrogen. National and institu-
tional guidelines were used for the care and use of animals,
and approval for the experiments was obtained. Lungs were
inflatedwith neutral buffered 10% formalin solution for about
24 h until adequate fixation. Each lung was dissected and
sections were embedded in paraffin. Several 5micrometres
sections from each inclusion were stained with a standard
hematoxylin and eosin staining protocol.
2.6. Statistical Data Analysis. All variables were tested
for normal distribution (D’Agostino-Pearson test). Data
were presented as means ± standard deviation or medi-
ans and interquartile range for normally distributed and
non-Gaussian continuous variables, respectively. Differences
between RTT and control groups were evaluated using
independent-sample t-test (continuous normally distributed
data), Mann-Whitney rank sum test (continuous nonnor-
mally distributed data), chi-square statistics (categorical vari-
ables with minimum number of cases per cell ≥5) or Fisher’s
exact test (categorical variables with minimum number of
cases per cell <5), one-way analysis of variance (ANOVA),
Student-Newman-Keuls post hoc test, or Kruskal-Wallis test,
as appropriate. Associations between variables were tested
by either parametric (Pearson’s coefficients) or nonparamet-
ric univariate (Spearman’s rho) regression analysis. Predic-
tive accuracy of apneas frequency/severity in identifying
enhanced OS markers in RTT patients was calculated using
a receiver operating characteristic curve (ROC) analysis, and
an area under the curve value >0.5 was accepted to indicate
good discrimination. The MedCalc version 12.1.4 statistical
software package (MedCalc Software, Mariakerke, Belgium)
was used for data analysis and a two-tailed 𝑃 < 0.05 was
considered to indicate statistical significance.
3. Results
3.1. Clinical Respiratory Dysfunction. Relevant demographic
clinical characteristics for the examined RTT population are
shown in Table 1. According to the specifically related items
in the severity scoring system, all patients showed clinical
signs for a respiratory dysfunction at different degrees, with
moderate or severe dysfunction being detectable on a clinical
basis in 81.6% (186/228) of the RTT patients.
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Figure 2: Representative pulmonary gas exchange abnormalities (GEA) patterns in patients with typical RTT and MeCP2 gene mutation:
(a) “low pattern” abnormality; (b) “high pattern” abnormality; (c) “simple𝑉/𝑄mismatch”; and (d) “mixed pattern” abnormality. Ventilation-
perfusion (𝑉/𝑄) inequalities (i.e., GEA) were detectable in 80.7% of the whole RTT population, whereas only 19.3% of the patients showed a
normal gas exchange. A “low” pattern (i.e., 34.8 of all GEA types in RTT) indicates the presence of perfusion in poorly ventilated pulmonary
areas; a “high” pattern (i.e., 39.8% of all GEA types) points out the existence of high ventilation in poorly perfused pulmonary areas; a mixed
pattern (i.e, 19.6% of all GEA types) is a combination of the former two patterns, while a “simple mismatch” (i.e., 5.9% of GEA types) is a𝑉/𝑄
uncoupling, showing a modest fraction of low 𝑉/𝑄 ratios (1 to 0.1) and a modest fraction of high 𝑉/𝑄 ratios (1 to 10).
3.2. Pulmonary Gas Exchanges. Gas pulmonary exchange
investigations demonstrated the existence of a variety of
ventilation-perfusion inequalities (Figure 2 and Table 2) in
more than 3/4 (i.e., 80.7%) of the whole RTT population; a
“low” pattern (i.e., presence of perfusion in poorly ventilated
pulmonary areas) was observed in 64 patients (28.1% of
the examined whole RTT population), a “high” pattern (i.e.,
high ventilation in poorly perfused pulmonary areas) in 73
cases (32%), and a simple “mismatch” in 11 cases (4.8%),
while a “mixed” pattern was present in 36 patients (15.8%).
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Table 1: Relevant demographic and clinical characteristics of female
subjects with Rett syndrome.
Variables
Patients (𝑁) 228
Age (years) 12.9 ± 7.9§
Body weight (RTT 𝑧-score for age)1 0.025 ± 1.12
Body height (RTT 𝑧-score for age)1 −0.05 ± 1.13
Head circumference (RTT 𝑧-score)1 −0.22 ± 1.11
Body mass index (BMI) (RTT 𝑧-score for age)1 −0.36 ± 1.45
Clinical severity score (CSS)2 17.4 ± 7.3
Tachypneaa 59 (25.9 %)
Respiratory dysfunction on a clinical basisb
+ 42 (18.4 %)
++ 127 (55.7 %)
+++ 59 (25.9 %)
Additional clinical features
Air-Sc 64 (28.1 %)
Severe GERDd 27 (11.8 %)
1Calculated 𝑧-scores for age are referred to a validated Rett syndrome-
specific growth charts [42]. 2Clinical severity score was defined according
to Neul et al., 2008 [7]. aTachypnea was defined as a respiratory rate >1.8
times (i.e., above the upper quartile) of the expected respiratory rate for
age and gender; brespiratory dysfunction was categorized based on the
corresponding Percy’s clinical severity scale item [41]; §mean ± SD; cAir-S:
abnormal air swallowing; dGERD: gastroesophageal reflux disease.
Overall, only 19.3% (44/228) of the RTT population showed a
physiological (i.e., coupled 𝑉/𝑄) gas exchange pattern (RTT
versus controls, chi-square: 138.472, DF = 4, 𝑃 < 0.0001; chi-
square for trend: 56.154, DF = 1, 𝑃 < 0.0001).
Pulmonary gas exchanges parameters (Table 2) detected
a general trend toward hyperventilation in the RTT patients,
withmean total ventilation rates (𝑉tot) of 6.3±3.6 L/min (95%
C.I. for the mean 5.8 to 6.7) versus 5.2 ± 2.1 L/min in the
control subjects (𝑃 = 0.0028). Hyperventilationwas absent in
the “low” pattern of GEA, while being extreme in the “high”
GEA pattern. Likewise, alveolar ventilation was the largest
in the “high” pattern subpopulation of patients, with alveolar
ventilation values usually >3 L/min for all GEA subcategories
that is volumetrically consistent ventilation.
Blood gas analyses in RTT patients confirmed the pres-
ence of a relative hypoxia (PaO
2
: 87.5 ± 18.1 versus 98.7 ±
6.5mmHg, difference ± SE: 11.2 ± 1.75, 95% C.I.: 7.76 to
14.6, 𝑃 < 0.0001) and hypocapnia (PaCO
2
: 35.2 ± 7.5 versus
42.8 ± 5.8mmHg, difference ± SE: 7.6 ± 0.08, 95% C.I.: 6.02–
9.18,𝑃 < 0.0001), whereas blood pHwas comparable between
RTT and healthy controls (7.417±0.043 versus 7.413±0.045;
difference ± SE: −0.004 ± 0.005854, 95% C.I.: −0.0138 to
0.005854, 𝑃 = 0.4252). When hypocapnia was accounted
for, standard PaO
2
values in patients were found to be on
average 17.6 ± 1.5% lower than those of their healthy control
counterparts (PaO
2
: 81.1 ± 15.3 versus 98.7 ± 6.5, difference
± SE: 17.6 ± 1.5, 95% C.I.: 14.66 to 20.54, 𝑃 < 0.0001) despite
a normal-to-increased total volume (𝑉tot) 5.8 ± 2.97 versus
5.2±2.3 L/min, difference ± SE: −0.6±0.317, 95% C.I.: −1.224
to 0.0239, 𝑃 = 0.0594.
Remarkably, larger differences in hyperventilation were
associated with consistently smaller intergroup differences
(1-way ANOVA, 𝑃 = 0.025) in PaO
2
and even smaller
differences when hypocapnia was accounted for (standard
PaO
2
, 𝑃 = 0.082), thus indicating a reduced efficiency of
pulmonary exchange despite normal pH values. However, the
physiological dead space, as calculated by the Bohr equation,
was found to be at the upper physiological limits (i.e., 30 to
45% of the 𝑉
𝑡
in the healthy control population) in the “no
mismatch,” “simple mismatch,” and “low” patterns (41.2 to
45.0 𝑉
𝑡
%), whereas it appears to be increased up to 55.4 ±
10.8𝑉
𝑡
% and 54.7 ± 15.5𝑉
𝑡
% in “high” and “mixed” patterns,
respectively. These findings confirm the occurrence of a
reduced efficiency of pulmonary exchanges in the RTT pop-
ulation, with a statistically significant relationship between
respiratory rate and Bohr’s physiological dead space (rho =
0.144, 𝑃 = 0.0303). Overall, oxygen uptake (𝑉O
2
) and carbon
dioxide production (𝑉CO
2
) values appear to be lower than
those of healthy controls subjects (𝑉O
2
: 250 to 300mL/min
and 𝑉CO
2
: 200 to 250mL/min, resp.). Likewise, respiratory
exchange ratios (i.e., 𝑉CO
2
/𝑉O
2
) in the RTT patients were
accordingly higher than those observed in healthy controls
(1.56 ± 1.23 versus 0.81 ± 0.32, 𝑃 < 0.0001).
3.3. Redox and Antioxidant Status. The results of the redox
and antioxidantmarkers inRTTpatients showed significantly
increased plasma levels of non-protein-bound iron (NPBI)
(∼2-fold), F
2
-isoprostanes (F
2
-IsoPs) (∼2.9-fold), reduced
glutathione (GSH) (∼1.4-fold), oxidized glutathione (GSSG)
(∼50-fold), and intraerythrocyte NPBI (IE-NPBI) (∼1.5-
fold) as compared to healthy control subjects (Table 3).
Consequently, a significantly decreased GSH/GSSG ratio
(∼ −15-fold) in patients was evidenced.
3.4. Cardiorespiratory Monitoring. Cardiorespiratory moni-
toring showed a significant prevalence of obstructive apnoeas
both during the sleep and the wakefulness states in RTT
patients, with median rates of obstructive apnoeas of
17.7/h and 6.2/h, respectively (Table 4). Of note, obstructive
episodes were more prevalent as compared to central events
by 25.3- and 15.5-fold during the wakefulness and sleep state,
respectively. The lowest recorded SpO2 values during the
apnoeic events were 78.8 ± 13.1%. Apneas during the sleep
phase were detectable in 63.6% (145/228) of patients, with a
mean AHI of 15.9± 4.69. Positive criteria for OSAHS (AHI >
15) were present in 27.2% (62/228) of the whole RTT patients
population.
3.5. Relationship between Redox Imbalance and Apnea Fre-
quency/Severity. Statistically significant positive correlations
were observed between recording of apneas, independently of
the degree of severity, and IE-NPBI (rho coefficients, range:
0.324 to 0.358; P values, range: 0.0024 to 0.0089) or GSSG
(rho coefficients range: 0.258 to 0.267; 𝑃 values, range: 0.0392
to 0.0156) (Table 5). On the other hand, positive relationships
between apneas and p-NPBI (rho: 0.265, 𝑃 = 0.0346) or F
2
-
IsoPs (rho: 0.305, 𝑃 = 0.0142) were also observed but limited
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Table 3: Redox/antioxidant status in patients with typical Rett syndrome: systemic oxidative stress with decreased GSH/GSSG ratio.
Redox and antioxidant markers Rett syndrome (𝑛 = 228) Healthy controls (𝑛 = 114) 𝑃 value
P-NPBI (nmol/mL) 0.90 ± 0.18 0.43 ± 0.25 <0.0001
IE-NPBI (nmol/mL) 1.20 ± 0.30 0.78 ± 0.17 <0.0001
F2-IsoPs (pg/mL) 70.1 ± 20.5 24.2 ± 11.5 <0.0001
GSH (𝜇mol/L) 1673.0 ± 591.0 1165.0 ± 132.0 <0.0001
GSSG (𝜇mol/L) 179.0 ± 73.9 3.55 ± 1.90 <0.0001
GSH to GSSG ratio 10.9 ± 5.5 160.0 ± 61.0 <0.0001
P-NPBI: plasma non-protein-bound iron; IE-NPBI: intraerythrocyte non-protein-bound iron; F2-IsoPs: plasma F2-isoprostanes; GSH: reduced glutathione;
GSSG: oxidized glutathione.
Table 4: Results of cardiorespiratory monitoring in patients with
typical Rett syndrome (𝑛 = 228) confirming a high frequency of
apneas and hypopneas either during wakefulness or sleep states.
Recorded events Median events/h Interquartile range
Sleep
Obstructive apneas 6.2 3.4–58
Central apneas 0.4 0.15–0.92
Mixed apneas 1.5 0.4–2.5
Hypopneas 25.6 20.1–34.7
Wakefulness
Obstructive apneas 17.7 4.9–11.38
Central apneas 0.7 0.08–1.07
Mixed apneas 1.7 0.92–2.4
Hypopneas 22 12.7–26
Apnoeas were defined as a >90% airflow decrease for ≥10 sec; hypopnoeas
were defined as a >50% airflow reduction for ≥10 sec associated with
a decrease of ≥3% in oxygen saturation [51]. Obstructive apneas refer
to recorded events with cessation of airflow for ≥10 sec associated with
persistent respiratory effort; central apneas refer to events characterized by
cessation of airflow for ≥10 sec without associated respiratory effort; mixed
apneas refer to respiratory events that begin as central apneas and end up as
obstructive apneas.
to the most severe events only. A significant inverse rela-
tionship between moderate apneas and GSH to GSSG ratio
was present (rho: −0.247, 𝑃 = 0.0488). An average number
of >7.4/h for total apneas, >0.8/h for moderate apneas, and
>2 for severe apneas (either recorded during wakefulness or
sleep states) were found to be predictive for increased IE-
NPBI plasma levels in patients, with 50% to 80.7% sensitivity,
55.3% to 82.02% specificity, 55.3% to 65% positive predictive
value, and 62.7% to 80.8% negative predictive value (𝑃 values
for the AUC, range: 0.0044 to 0.0163) (Table 6). In contrast,
frequency/severity of the recorded apneas was not predictive
for plasma levels of F
2
-IsoPs in RTT patients (𝑃 values for the
AUCs, range: 0.3149 to 0.9487).
3.6. Relationship between Redox Imbalance and Pulmonary
Gas Exchange Abnormality. When evaluated as a function
of GEA in RTT, striking differences in the redox/antioxidant
markers levels were detectable among the different categories
of pulmonary𝑉/𝑄 inequality, ranging from values compara-
ble to those of the control group in the “no mismatch” group
Table 5: Correlation matrix between redox/antioxidant status and
severity of recorded apnoeas, either during wakefulness or sleep, in
patients with typical Rett syndrome (𝑁 = 228).
Redox and antioxidant
markers
Apnoeas
Mild Moderate Severe
P-NPBI 0.185(0.1431)
0.176
(0.1631)
0.265
(0.0346)
IE-NPBI 0.324(0.0089)
0.373
(0.0024)
0.358
(0.0037)
F2-IsoPs
0.2220
(0.0800)
0.225
(0.0744)
0.305
(0.0142)
GSH 0.252(0.0449)
0.101
(0.4262)
0.183
(0.1485)
GSSG 0.258(0.0392)
0.260
(0.0378)
0.267
(0.033)
GSH/GSSG ratio −0.210(0.0961)
−0.247
(0.0488)
−0.241
(0.0552)
Data are expressed as rank correlation rho coefficients with 𝑃 values
in brackets. Bold characters indicate statistically significant associations.
Apnoeas were defined as a >90% airflow decrease for ∼10 sec; hypopneas
were defined as a >50% airflow reduction for ≥10 sec associated with a
decrease of≥3% in oxygen saturation [50]. Apnoeas were further categorized
asmild (10 to 15 sec),moderate (15 to 30 sec), and severe (>30 sec) on the basis
of their recorded duration. Legends: P-NPBI: plasma non-protein-bound
iron; IE-NPBI: intraerythrocyte non-protein-bound iron; F2-IsoPs: plasma
F2-isoprostanes; GSH: reduced glutathione; GSSG: oxidized glutathione.
to significant redox/antioxidant imbalance in the various
GEA patterns (Table 7). In particular, F
2
-IsoPs plasma levels
were approximately proportional to the degree of severity
for 𝑉/𝑄 abnormality, with increase of ∼1.7-fold for “simple
mismatch,” ∼2.4-fold for “low” patterns, ∼2.8-fold for “high”
patterns, and ∼3.7-fold for “mixed” patterns, as compared to
patients without detectable GEA.
3.7.MutantMecp2Murine LungHistology. The results of lung
histology in the Mecp2 null RTT mouse models showed a
picture of nonspecific lymphocytic bronchiolitis associated
with lymphocytic vasculitis (Figures 3(b) and 3(d)) and
desquamative alveolitis in a half of the examined mutant
mice, whereas no significant histological abnormalities were
observed in the wt animals.
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Table 6: Frequency/severity of apneas, recorded during either thewakefulness or sleep, identifies Rett patientswith increased intraerythrocyte
non-protein-bound iron (IE-NPBI) levels: receiver operating characteristic (ROC) curves analyses.
Variable AUC ± SE 95% C.I. 𝑃-value Criterion Sens.% Spec.% +LR −LR +PV −PV
Total apneas/h 0.690 ± 0.0669 0.563–0.799 0.0044 >7.4 53.8 82.05 1.5 0.89 56.2 62.7
Mild apneas/h 0.634 ± 0.0714 0.504–0.751 0.0605 >1 30.7 89.5 1.54 0.51 51.4 74.1
Moderate apneas/h 0.664 ± 0.0687 0.563–0.778 0.0163 >0.8 80.7 55.3 1.81 0.35 55.3 80.8
Severe apneas/h 0.670 ± 0.0693 0.541–0.782 0.0142 >2 50 81.6 2.71 0.61 65 70.5
AUC: area under the curve; SE: standard error; Sens.: sensitivity; Spec: specificity; +LR: positive likelihood ratio; −LR: negative likelihood ratio; +PV: positive
predictive value; −PV: negative predictive value. Bold characters indicate statistically significant items.
Table 7: Relationships between lung ventilation/perfusion (𝑉/𝑄) patterns and the redox/antioxidant status in patients with typical Rett
syndrome (𝑛 = 228).
Redox and
antioxidant markers
Pulmonary ventilation/perfusion (𝑉/𝑄) patterns in typical Rett syndrome
𝑃 value
(ANOVA)No mismatch(𝑁 = 44)
“Low”
(𝑁 = 64)
“High”
(𝑁 = 73)
“Mixed”
(𝑁 = 36)
“Simple” mismatch
(𝑁 = 11)
P-NPBI (nmol/mL) 0.50 ± 0.32a 0.86 ± 0.07a,b,c 0.91 ± 0.15a 1.02 ± 0.22a,b,c 0.71 ± 0.05b,c <0.001
IE-NPBI (nmol/mL) 0.80 ± 0.24a 1.04 ± 0.05a,b 1.20 ± 0.21a,b 1.30 ± 0.49a,b 0.96 ± 0.13b <0.001
F2-IsoPs (pg/mL) 27.3 ± 11.1a 65.2 ± 14.4a,b 76.5 ± 13.2a,b 100.8 ± 11.4a,b 46.2 ± 7.9b <0.001
GSH (𝜇mol/L ) 1206 ± 140a 1867 ± 759a,b 1794 ± 507a,b 1442 ± 373a,b 1419 ± 523b <0.001
GSSG (𝜇mol/L ) 8.0 ± 3.4a 193.6 ± 85.3a,b 222.5 ± 61.5a,b 132.0 ± 25.9a 144.3 ± 71.4b <0.001
GSH/GSSG ratio 175 ± 83a 12.2 ± 7.8a 8.2 ± 1.9a 11.6 ± 5.1a 11.1 ± 5.2a <0.001
Data are expressed asmeans± SD. Bold characters indicate statistical significant differences; superscript letters indicate significant pairwise post hoc differences;
P-NPBI: plasma non-protein-bound iron; IE-NPBI: intraerythrocyte non-protein-bound iron; F2-IsoPs: plasma F2-isoprostanes; GSH: reduced glutathione;
GSSG: oxidized glutathione.
4. Discussion
Respiratory dysfunction in RTT appears to be far more
complex than previously thought. Specifically, the findings
of the present study indicate that, besides brainstem dys-
function, several intertwined critical factors, either directly
or indirectly related to the disease, appear to concur to
adversely affect respiratory function in RTT patients. In
particular, our findings strongly support the hypothesis that
the respiratory behavior in RTT, historically credited to
neurological dysfunction, can be considered as the result
of a previously unrecognized inflammatory process and/or
abnormal immune response [55].
Abnormal pulmonary gas exchange, as the result of the
imbalance between 𝑉 and 𝑄, is a main cause of hypoxemia
[56]. While confirming the coexistence of a relative hypoxia
(−17.6 ± 1.5% as compared to a cohort of healthy controls;
95% C.I.: −14.66 to −20.54) and abnormal pulmonary gas
exchange in over 3/4 of the patients with typical RTT, we
identified for the first time the relative distribution for the
different GEA patterns. GEA was detectable in ∼80% of the
RTT patients, with “high” and “low” patterns dominating
over “mixed” and “simple mismatch” types of pulmonary
𝑉/𝑄 inequalities. This 𝑉/𝑄 behavior here observed could be
linked to either the presence of unventilated pulmonary areas
in the low patterns (i.e., unrecognized pulmonary dysventila-
tion or microatelectasis) or unperfused areas in the high pat-
terns (i.e., unrecognized pulmonarymicroembolism).There-
fore, our findings strongly suggest that GEA is a key feature
of respiratory dysfunction in RTT that brainstem immaturity
[9, 12] and/or cardiorespiratory autonomic dysautonomia
[13, 14], both repeatedly evoked in the disease, are per se
evidently unable to explain. It is interesting to observe that
several features of the respiratory behaviour observed in
RTT patients, chiefly hyperventilation, can be interpreted
as compensatory mechanisms rather than the effects of
dysfunctional brainstem activity and/or cardiorespiratory
autonomic dysautonomia. However, hyperventilation, as a
likely compensatory mechanism in order to overcome the
negative effects of GEA, can lead to an adverse increase of the
physiological dead space, as thus reducing the fraction of ven-
tilation that effectively participates in alveolar gas exchanges.
In addition, hyperventilation can lead to severe hypocapnia,
a very frequent finding in RTT, thus further decreasing
the effective (i.e., normalized to PaCO
2
) PaO
2
levels. The
observed decrease in 𝑉O
2
and 𝑉CO
2
could also be potentially
regarded as possible effects of compensatory mechanisms,
although more investigation is needed to understand this
unexpected feature of the RTT lung pathophysiology.
OSAHS is described as repetitive obstructions of the
upper airways during sleep, causing concomitant episodes
of systemic hypoxia and associated cardiovascular and
metabolic pathologies, with an estimated prevalence of 0.7%
to 1.8% in the general paediatric population [57–62] and of
2% for adult women and 4% for adult men [63–65]. The
condition can be difficult to diagnose clinically, although
even mild-to-moderate obstructive sleep apnoea can result
in adverse neurobehavioral consequences and negatively
affect quality of life [58, 59]. Our cardiorespiratory mon-
itoring data in a relatively large cohort of RTT patients
indicate a significantly increased prevalence ofOSAHS in this
patient population (i.e., 27.2%) and confirm the presence of
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Wild-type mouse
(a)
Mecp2 null mouse
(b)
Mecp2 null mouse
(c)
Mecp2 null mouse
(d)
Figure 3: Lymphocytic bronchiolitis and desquamative alveolitis in Mecp2 null mice. (a) Wild-type mouse lung: normal histological
features (magnification 25x), (b) Mecp2 null mouse: peribronchiolar lymphocyticinfiltrate (magnification 50x), (c) Mecp2 null mouse lung:
desquamative alveolitis with mild amount of alveolar exudate (50x), and (d) Mecp2 null mouse lung: terminal bronchiolitis at higher
magnification (200x) lymphocytes and histiocytes infiltrates outside and inside thickened terminal bronchioles, with a resulting picture of
lymphocytic bronchiolitis.
clinically significant apneas also during wakefulness. These
findings indicate that RTT should be added to the list
of the already known heterogeneous pediatric conditions
carrying an increased risk for OSAHS, including Down’s
syndrome, neuromuscular disease, craniofacial abnormal-
ities, achondroplasia, mucopolysaccharidoses, and Prader-
Willi syndrome. Although the overwhelming majority of
previous polysomnographic studies in RTT patients have
reported a prevalence of apnoeas of central origin [15–26],
our findings indicate that obstructive apnoeas are far more
common in typical RTT than previously reported.
Human and experimental evidence indicate that OSAHS
and intermittent hypoxia can be associated with enhanced
OS, although conflicting reports exist [66–76]. In the present
study, we confirm the coexistence of a significant redox
abnormality in RTT patients. However, the relationship
between upper airways obstruction/intermittent hypoxia and
OS status in RTT appears to be limited to the generation of
a prooxidant status, as indicated by the link here observed
between IE-NPBI, but not F
2
-IsoPs, and apneas. Iron is a
major player in redox reactions, as it has been known for
a long time that redox-active iron is one of the most active
sources of OS [77]. Furthermore, iron release is much higher
under hypoxic conditions than under normoxia [78, 79],
so that hypoxia paradoxically represents a condition of OS
that is consistent with a condition of ischemia-reperfusion
injury. Released iron can diffuse out of the erythrocytes
and the diffusion is higher with hypoxic erythrocytes [79].
Intermittent hypoxia can affect the stability of the bond of
iron to the tetrapyrrole ring of protoporphyrin, thus releasing
iron inside the erythrocytes, along with hemoglobin autox-
idation [80]. However, it becomes clear that mechanisms
other than intermittent hypoxia should be the major sources
of enhanced OS in RTT. Actually, in the present study,
we observed a very intimate relationship between redox
abnormality and GEA in RTT. These results suggest that
chronic, rather than intermittent, hypoxia resulting from
a pulmonary 𝑉/𝑄 inequality is likely the main source of
systemic OS in RTT. To this regard, it is of relevance that
we detected a dramatic increase of GSSG in RTT patients,
with a parallel dramatic decrease of theGSH/GSSG ratio, thus
strongly suggesting the coexistence of a chronic OS status.
While future studies are obviously needed to address
this major topic, several other factors apparently concur to
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adversely affect the respiratory function and, either directly
or indirectly, contribute to pulmonary gas exchanges impair-
ment in RTT patients. These factors likely include abnor-
mal erythrocyte shape with oxidative membrane damage
[81], microvascular dysplasia [82], alterations in the vascu-
lar/endothelial system [83], mitochondrial dysfunction [84–
87], subclinical biventricular myocardial dysfunction [88],
systemic oxidative stress [29, 35], and, chiefly, subclinical
inflammatory processes [38, 55].
Over the last decade, several experimental animal models
have been developed in which the Mecp2 allele has been
modified to prevent production of a fully functional Mecp2
protein. In particular, several experimental mouse models
of Mecp2 deficiency have been established in mice, rang-
ing from null-Mecp2 mutations to specific point mutations
mimicking those observed in humans, phenocopying several
motor and cognitive features of RTT patients. In particular,
the irregular breathing pattern observed in human RTT has
been replicated in several mutant mouse models to varying
degrees of fidelity, although the corresponding respiratory
phenotype varies among differentmouse strains [89–91], with
mutations in theMecp2 gene leading to disparate respiratory
phenotypes. For instance, in Mecp2tm1.1Jae null (hemizy-
gous) mice on a mixed-strain background [92], the principal
phenotype is tachypnea along with hyperventilation similar
to human RTT [93], whereas in Mecp2tm1.1Bird null or
heterozygous mice on a pure C57BL/6J background [94] the
principal phenotype is repetitive spontaneous central apnea
[95–97], whereas the Mecp2tm1.1Bird male mice provide
an excellent animal model of spontaneous central apnea
and possibly obstructive apnea [28]. A more recent study
indicates that a clinically relevant RTT endophenotype, that
is, tachypnea with a shortened expiratory time, appears to
be more faithfully reproduced in Mecp2tm1.1Jae female mice
[98]. Despite the fact that MeCp2 mutant mouse models
cannot model all aspects of the human RTT, certainly they
do recapitulate many aspects of the disease and are generally
accepted as excellent tools to study MeCP2 function. In this
context, our findings of a lymphocytic bronchiolitis in a half
of the examined Mecp2-null mice are highly suggestive of a
previously unrecognized inflammatory lung disease in RTT
patients and are well fitting with our prior observations of
radiological features at high-resolution computed tomogra-
phy partially overlapping with those of RB-ILD [38] and
including micronodules (i.e., inflammatory infiltrates in the
smaller airways, such as terminal bronchioles and/or alveoli),
“ground glass opacities” (i.e., radiological signs of alveolar
inflammation), and, remarkably, thickening of bronchiolar
walls (a radiological sign of inflammatory infiltrates in the
terminal bronchioles). Further studies are obviously needed
in different Mecp2-mutant animal models in order to ascer-
tain prevalence and possible differences related to different
mouse strains.
Cumulating evidence indicates that RTT is a multi-
systemic disease, which, besides the brain, is known to
affect several organs and systems, including the autonomic
nervous system [12–14], microvascular/endothelial system
[12, 13], bone [99], heart [88, 100], red blood cells [81],
the gastrointestinal tract [101], and the immune system
[102, 103]. Our study strongly supports the concept that
the lung is a previously unrecognized major target organ
in this genetically determined neurodevelopmental disease
and that pulmonary GEA is likely a key feature within the
multisystemic characteristics of the disease.
5. Conclusions
The findings of the present clinical study confirm the emerg-
ing concept according to which no single putative mecha-
nism can account for all the complexity of the respiratory
behaviour exhibited by RTT patients. The present study
indicates that (1) pulmonary GEA, not brainstem immaturity,
is likely the key feature of respiratory dysfunction in RTT;
(2) the RTT-related GEA is likely the result of several
contributing factors, involving OS and chronic subclinical
inflammation; and (3) terminal bronchioles and alveoli are
likely a major, under-recognized, inflammatory target of the
disease.Moreover, these data confirm the clinical relevance of
respiratory dysfunction in this rare neurological disease as a
valuable pathophysiologicalmodel for a better understanding
of the complex involvement of the lung in a multisystemic
disease. Our findings strongly support the hypothesis that the
respiratory behavior in RTT, historically credited to neuro-
logical dysfunction, is rather the result of an inflammatory
process and/or abnormal immune response.
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